learningmedicine: August 2026

Sunday, August 23, 2026

Decoding the Bharatiya Nyaya Sanhita, 2023, for Doctors: A Grand Rounds on India's New Criminal Code

A clinician's guide to the law that now sits at the foot of every Indian hospital bed

Dr Neeraj Manikath. DNB

Grand Rounds Summary On 1 July 2024, the Indian Penal Code, 1860 — the statute under which every Indian doctor has practised, been sued, and occasionally been arrested — was repealed and replaced by the Bharatiya Nyaya Sanhita, 2023 (BNS). This review translates the sections of the BNS that actually touch clinical practice into the language clinicians think in: pearls, oysters, hacks, and escalation thresholds — the same way we teach a new disease.

1. The Case That Changes Everything

A 34-year-old primigravida is rushed into the labour room of a district hospital at 2 a.m. with abruptio placentae. The on-call obstetrician performs an emergency caesarean. The baby is stillborn; the mother survives but loses her uterus to a hysterectomy for uncontrolled atonic haemorrhage. Two months later, the husband — egged on by a local activist group — files a police complaint alleging that "the doctor was careless and killed my child and destroyed my wife's future."

The obstetrician, who followed every line of the FOGSI protocol and documented meticulously, is issued a notice to appear before the local police station. She has practised for eleven years and has never been named in a criminal complaint. She does not know whether what she is now facing falls under a law she has never read — because it did not exist when she finished her MD.

This is the epidemiological hook: since 1 July 2024, every first information report (FIR) against a doctor in India — for alleged negligence, for a hospital-floor assault by a patient's relatives, for a disputed death certificate, for a termination of pregnancy gone wrong, for an unwitnessed dying declaration — is now registered not under the IPC, but under the Bharatiya Nyaya Sanhita, 2023. The Indian Medical Association estimates that over 100,000 doctors face at least one medico-legal notice annually in India;1 almost none of them have had formal training in the statute that now governs their liability. This article exists to close exactly that gap.

🩺 Why this matters clinically, not just legally: The law does not just determine what happens after an adverse event — it shapes what good documentation, informed consent, and escalation behaviour look like before one. A clinician who understands Section 106 practises differently, and better, than one who doesn't.

2. "Pathophysiology": The Anatomy of the New Code

Just as we would not discuss management of an arrhythmia without first understanding the conduction system, we cannot discuss doctors' liability without understanding how the BNS is built.

The three-act replacement. The BNS is one of three companion statutes that together replaced the entire colonial-era criminal framework on 1 July 2024:

Old statute (IPC-era)	New statute	Governs
Indian Penal Code, 1860	Bharatiya Nyaya Sanhita, 2023 (BNS)	Substantive offences — what is a crime, and what punishment it carries
Code of Criminal Procedure, 1973	Bharatiya Nagarik Suraksha Sanhita, 2023 (BNSS)	Procedure — arrest, investigation, medical examination of the accused/victim, forensic sample collection
Indian Evidence Act, 1872	Bharatiya Sakshya Adhiniyam, 2023 (BSA)	Evidence — what a court may admit, including electronic and medical records

This review focuses on the BNS — the substantive code — because that is the statute that names the offence a doctor may be charged with. But a clinician should know the other two exist; when a patient's relative demands "medical examination of the accused" or a magistrate orders forensic evidence collection, that is BNSS territory, and the medico-legal certificate you sign is governed by BSA's rules of evidence.

The renumbering trap. The BNS compresses the IPC's 511 sections into 358 sections across 20 chapters.2 Crucially, the section numbers you memorised in your MBBS forensic medicine posting no longer apply. Section 302 (murder) is now Section 103. Section 304A (death by negligence) is now Section 106. Section 375/376 (rape) is now Sections 63–70. This is not cosmetic — old textbooks, old judgments cited by name ("a 304A case"), and old hospital protocol documents are all now speaking a dead legal dialect.

🩺 Clinical pearl analogy: Think of this the way you'd think of a drug being rebranded with a new generic name after a formulary change — same molecule in places, different molecule in others, and prescribing from memory is how errors happen.

What actually changed for medicine — and what didn't. The overwhelming majority of BNS provisions are renumbered restatements of IPC law with only linguistic modernisation. But three areas underwent substantive change that every clinician must know cold:

A new, separate, lower-punishment provision for registered medical practitioners causing death by negligence during a medical procedure (Section 106(1)).
A new offence of mob violence/lynching (Section 103(2)) — directly relevant to the epidemic of violence against on-duty doctors.
New and modified sexual-offence provisions (Sections 63–70) affecting how doctors conduct and certify medico-legal examinations, and a new offence of "sexual intercourse by deceitful means" (Section 69) with direct relevance to reproductive medicine.

Everything else in this article builds on these three structural facts.

3. Clinical Pearls 🪙 — Bedside-Level, Counterintuitive Points

🪙 Pearl 1 — "304A" is dead; say "106." If your hospital's incident-reporting SOP, your indemnity insurance policy wording, or your consent form still cites "Section 304 IPC," it is legally obsolete for any event after 1 July 2024. Audit your documents now, not after a notice arrives.

🪙 Pearl 2 — The reduced punishment under Section 106(1) applies only to a "registered medical practitioner" performing a "medical procedure." The statute defines a registered medical practitioner precisely: someone holding a qualification recognised under the National Medical Commission Act, 2019, and entered in the National Medical Register or a State Medical Register.3 An AYUSH practitioner performing allopathic prescribing, an unregistered intern acting alone, or a quack does not get this protection — and neither, arguably, does a fully qualified doctor whose registration has lapsed for non-renewal of continuing medical education credits in states where that is now mandatory. Check your registration status the way you check your DEA-equivalent narcotics licence — proactively, not reactively.

🪙 Pearl 3 — General negligence causing death still carries up to 5 years; the doctor-specific carve-out caps it at 2 years — but only for the negligence limb, not for larger charges. If facts support a graver charge — culpable homicide (Sections 100–101) or murder (Section 103) — for instance, gross, reckless departure from standard of care with foreseeable death, the milder Section 106(1) proviso is irrelevant. The protection is for genuine negligence, not for recklessness dressed up as an accident.

🪙 Pearl 4 — "Hurt" is now Section 114, "grievous hurt" is Section 116, and this matters every time you write a medico-legal certificate (MLC). The eight categories of grievous hurt are unchanged in substance from the old IPC list but are worth re-memorising because your MLC wording is the single document a magistrate reads to decide the severity of the charge against an assailant.4

🪙 Pearl 5 — Acid attack now carries a statutory minimum of 10 years, extendable to life (Section 124).5 For burns units and plastic surgery departments, this raises the evidentiary stakes of your acid-attack documentation (concentration, distribution pattern, depth) considerably — a vague MLC can be the difference between a 10-year minimum sentence and an acquittal on technical grounds.

4. Oysters 🦪 — Hidden Gems Most Clinicians Miss

🦪 Oyster 1 — "Community service" is now a recognised sentence under the BNS for the first time in Indian criminal law history, for specified minor offences.2 Doctors serving as expert witnesses or medical board members in disciplinary matters should know this option exists — it changes plea and sentencing conversations you may be asked to advise on.

🦪 Oyster 2 — Mob violence against doctors can now itself be prosecuted as "mob lynching," not just as simple assault. Section 103(2) criminalises murder committed by five or more persons acting in concert on grounds including... any other similar ground, with punishment up to death or life imprisonment.6 While drafted with communal/caste violence in mind, hospital administrators and legal cells increasingly cite this section — alongside the specific hospital-violence Acts many states already have — when relatives attack on-duty staff after a death. Know that the charging framework for hospital mob violence has broadened, even if the primary tool for doctors remains state-specific Medical Service Persons and Institutions Acts.

🦪 Oyster 3 — Section 69 criminalises "sexual intercourse by deceitful means," explicitly including a false promise of marriage or concealment of identity.7 This is a new, codified offence (distinct from rape) carrying up to 10 years. Gynaecologists and reproductive medicine specialists will increasingly see this cited in cases involving disputed consent for pregnancy, abortion, or ART procedures — understand that this is now a named statutory offence, not merely a civil grievance.

🦪 Oyster 4 — The age threshold for "gang rape" victims requiring the enhanced-punishment provision was raised to under 18 years, aligning the BNS more closely with the POCSO Act's minor-protection framework.8 For paediatricians and adolescent-medicine physicians conducting examinations in suspected sexual assault of a minor, this closes what used to be an interpretive gap between IPC's rape provisions and POCSO.

🦪 Oyster 5 — Sedition is technically "repealed" as a named offence, but Section 152 criminalises acts that "endanger the sovereignty, unity and integrity of India," a broader and, per critics, vaguer formulation.2,9 This is not directly clinical, but hospital administrators and medical college heads dealing with student unrest, protest documentation, or public statements about health policy should be aware the successor provision exists and carries life imprisonment as a possible sentence — it is not "sedition abolished," it is "sedition renamed and reshaped."

5. Clinical Hacks & Tips ⚡ — Practical Shortcuts

⚡ Hack 1 — The "Five Ws" documentation reflex. Before you sign anything — a discharge summary, an MLC, a death certificate, a consent form — write down: Who consented, What was explained (including alternatives and risks), When (timestamp), Witness (nurse/relative), and Why (clinical indication). In a Section 106 negligence inquiry, this single habit converts "he said/she said" into a documented standard-of-care trail. Courts under the new BSA rules on electronic evidence now more readily accept properly authenticated digital records — so a time-stamped EMR note is more, not less, protective than it was under the old Evidence Act.10

⚡ Hack 2 — Keep a personal, dated log of registration renewal and CME compliance. Since the Section 106(1) proviso hinges entirely on your status as a "registered medical practitioner," a lapsed renewal — even a clerical one — theoretically strips you of the reduced-punishment shield. Treat your State/National Medical Register entry like an active prescription that needs periodic renewal, not a one-time certificate.

⚡ Hack 3 — When a relative threatens violence, invoke the specific state Medical Protection Act by name, and note in the incident file that "mob violence" as understood under BNS Section 103(2)/117(4) may also apply if serious injury results. Hospital security and legal teams respond faster to a specific citation than to a vague "this is illegal" — naming the section signals you know exactly what you're invoking.

⚡ Hack 4 — For MLC writing, use the BNS's own eight-point grievous-hurt checklist as a structured template, rather than free text. Ticking through (a) emasculation, (b) loss of sight, (c) loss of hearing, (d) loss of a limb/joint, (e) destruction of limb/joint function, (f) permanent facial disfigurement, (g) fracture/dislocation, (h) hurt endangering life or causing 15+ days of severe pain/incapacity4 — forces completeness and creates a document a magistrate can act on without needing clarification, which shortens your time in court as a witness later.

⚡ Hack 5 — Before any consent conversation for a high-risk procedure, mentally run the "reasonable and competent practitioner" test (the Bolam-derived standard Indian courts still apply when assessing Section 106 negligence): would a reasonable body of medical opinion have acted as you did? Documenting why you chose a particular course over an alternative — not just that you chose it — is the single strongest defence against a negligence charge.11

🦪 Oyster 6 — Attempt to commit suicide has effectively fallen out of BNS as a standalone criminal offence for the person themselves (mirroring the decriminalisation already achieved via the Mental Healthcare Act, 2017), but abetment of suicide (Sections 108–109) has been retained and, in places, sharpened, including specific provisions on abetment of suicide by a child, a person of unsound mind, or an intoxicated person. For psychiatrists and emergency physicians managing deliberate self-harm presentations, this distinction matters: your patient is not a criminal defendant, but anyone found to have coerced, harassed, or driven them to the act may be. Document any disclosed history of coercion, harassment, or abetment carefully and neutrally — it may become relevant evidence, but your clinical note should record what the patient reports, not a legal conclusion.

🦪 Oyster 7 — "Organ trade" and related bodily-harm-for-profit offences are addressed obliquely through existing provisions on grievous hurt, cheating, and criminal conspiracy rather than a single dedicated BNS section — transplant surgeons should remember that the primary regulatory statute for organ transactions remains the Transplantation of Human Organs and Tissues Act, 1994 (as amended), and the BNS applies only where the underlying conduct also independently constitutes hurt, cheating, or coercion. Do not assume the BNS itself creates a transplant-specific offence; it doesn't — but it stacks on top of THOTA violations when bodily harm or deception is also proven.

6. State-of-the-Art Updates — What's Changed, and What's Still Moving

🔄 The IMA's ongoing advocacy. The Indian Medical Association formally protested Section 106(1) upon enactment, seeking complete exemption of doctors from criminal liability for negligence (arguing for civil/disciplinary remedies only, as in several other jurisdictions). The Union Government's response has been that the 2-year cap under Section 106(1) is itself the concession — clarifying that under the old Section 304A IPC, doctors faced the same up-to-5-year exposure as anyone else, and that the new provision is protective, not punitive, relative to the prior regime.12,13 This tension is unresolved and is the single most litigated medico-legal issue arising from the BNS. Expect further amendment or judicial clarification; track IMA and National Medical Commission circulars.

🔄 Judicial course-correction is already happening. Within a year of enactment, the Jharkhand High Court took suo motu cognizance of a printing/drafting discrepancy in Section 103(2) (mob lynching) where "any other ground" had been printed instead of the intended "any other similar ground" — a difference with real interpretive consequences — and directed correction.14 This illustrates a broader state-of-the-art point: the BNS text is still being actively refined through errata and judicial interpretation, and clinicians (and hospital legal cells) should not treat any single online reproduction of the Act as final without cross-checking the Gazette notification.

🔄 Digital and AI-era offences now sit inside the mainstream criminal code, not a separate IT-Act silo — organised cybercrime (Section 111) and identity-theft-related cheating (Section 316(5)) are now BNS offences.2 As telemedicine, AI-assisted diagnosis, and digital health records expand, doctors should recognise that data breaches, impersonation in teleconsultation, and AI-generated misdiagnosis-adjacent fraud claims may increasingly be framed under these BNS provisions rather than purely under the Information Technology Act or the DPDP Act, 2023.

🔄 The three-code architecture (BNS/BNSS/BSA) increasingly interlocks with the Digital Personal Data Protection Act, 2023, and NMC's Registered Medical Practitioner (Professional Conduct) Regulations, 2023. A single adverse event today may trigger parallel BNS criminal exposure, NMC/State Medical Council disciplinary proceedings, Consumer Protection Act civil liability, and DPDP data-breach obligations — a "quadruple jeopardy" clinicians increasingly need integrated legal counsel, not siloed advice, to navigate.

🔄 Community service as a sentencing option is being watched closely by medical defence bodies as a potential off-ramp for genuinely minor, first-instance negligence findings that nonetheless meet the technical threshold of Section 106(1) — though as of this writing there is no reported case of a doctor receiving a community-service disposition under BNS, medico-legal commentators expect test cases within the next few years given the government's stated intent to reduce incarceration for non-violent, non-recidivist offences.2

🔄 State-level implementation variance is real and clinically relevant. Because policing and prosecution are largely state subjects in India, the practical experience of a Section 106 FIR — how quickly it is registered, whether investigating officers seek expert medical board opinion before framing charges, and how readily anticipatory bail is granted — varies significantly by state. Kerala, Maharashtra, and Delhi have relatively well-established protocols requiring a medical board opinion before a doctor is arrested in a negligence case (a protection that predates the BNS and continues under it, per Supreme Court guidance in Jacob Mathew v. State of Punjab, whose principles courts continue to apply to BNS Section 106 cases). Clinicians in states without such established protocol layers should be proportionately more vigilant about the documentation habits described in this article.

7. Diagnostic Nuances — Separating the Good Clinician from the Great One

Just as a great clinician elicits the one history detail that changes the differential, a legally astute clinician elicits and documents the details that change how an incident will be classified under BNS.

History-taking nuance: When a patient presents after an assault, the timing of onset of symptoms relative to the alleged act (immediate vs delayed) determines whether the injury is classified as simple hurt (Section 114) or grievous hurt under the "15 days of severe pain or incapacity" clause (Section 116(h)) — a detail easy to omit if you're focused purely on clinical management.
Examination nuance: For any injury with medico-legal implications, examine and document bilaterally symmetric structures even when only one side is injured (e.g., document both pupils, both hands) — asymmetric documentation is a common cross-examination target used to suggest incomplete assessment.
Documentation nuance — the "procedure" boundary. Section 106(1)'s reduced punishment applies specifically to negligence "while performing medical procedure."3 Whether an act is a "medical procedure" is not statutorily defined further — meaning triage decisions, telephone advice, and administrative/staffing failures may fall outside this protective language, exposing the ordering physician or the institution to the general (up to 5-year) provision rather than the doctor-specific one. Document clinical reasoning at every decision point, not only during hands-on procedures — the boundary of "procedure" is where litigation strategy is currently being tested.
Investigation nuance — chain of custody now matters more, not less. Under the companion BSA, electronic records (EMR entries, PACS images, lab result timestamps) are admissible with a certificate of authenticity, similar to Section 65B of the old Evidence Act but modernised.10 A radiology report with an unverifiable timestamp, or a lab value entered retrospectively, is now a specific vulnerability a defence or prosecution lawyer will probe.
The dying declaration nuance. In cases of dowry death (Section 80, replacing the old Section 304B) or any death "otherwise than under normal circumstances," a dying declaration recorded by the treating doctor — in the patient's own words, with a note on the patient's fitness to make a statement — remains one of the most powerful pieces of evidence in Indian criminal law. A doctor who records "patient stated X" without first documenting a mental-status/fitness assessment weakens the declaration's evidentiary weight — this single habit is worth teaching in every emergency medicine curriculum.
The consent-conversation nuance. With Section 69's new, explicit criminalisation of sexual intercourse obtained through concealment of identity or a false promise of marriage, gynaecologists managing pregnancy termination requests, fertility counselling, or STI-related care will increasingly encounter patients disclosing that consent to the underlying sexual relationship — not to the medical procedure itself — is contested. The critical diagnostic separation for the clinician is: your duty is informed consent to the medical procedure before you; you are neither obligated nor equipped to adjudicate the validity of consent to the underlying relationship. Document what the patient consents to for treatment purposes; do not record editorial judgements about the alleged deceit, which is a matter for investigation, not for the chart.
The "otherwise than under normal circumstances" trigger. This exact phrase — carried over verbatim from the old Section 304B into the new Section 80 — is what obliges a doctor to stop and route a death through inquest/police channels rather than issuing a routine death certificate. Any death within seven years of marriage that is unexplained, sudden, related to burns, or associated with a history (even second-hand, from other patients or staff) of harassment must trigger this pathway. When in doubt, treat "recently married woman, unexpected death" as a mandatory-reporting trigger, not a judgement call — under-recognition here is one of the most common and consequential documentation failures in Indian hospital practice.

8. Management Intricacies — Sequencing the Response to a Medico-Legal Event

⚠️ Callout: The first hour matters as much medico-legally as it does clinically.

Step 1 — Stabilise the patient; document contemporaneously. Clinical care always precedes legal considerations, but contemporaneous documentation (not backdated, not reconstructed days later) is the single strongest protective factor in any subsequent Section 106 inquiry.

Step 2 — Preserve, don't editorialise. Retain original charts, drug charts, monitor strips, and consent forms unaltered. Do not "clean up" notes retrospectively — under BSA's evidence rules, metadata trails on EMR edits are discoverable, and a late edit is read far more suspiciously than an incomplete original note.

Step 3 — Notify institutional risk management/legal cell and your indemnity insurer within 24–48 hours, even before a formal complaint is filed, if you sense an adverse outcome may generate one. Most professional indemnity policies (IMA-sponsored or private) have notification clauses; delayed notification can jeopardise coverage independent of the BNS proceedings themselves.

Step 4 — Cooperate with, but do not volunteer beyond, a police inquiry. Under BNSS procedure (the companion procedural code), a doctor is entitled to have legal counsel present during questioning related to a Section 106 matter. Politely decline to give a statement without counsel present if the matter has progressed to formal investigation — this is standard practice, not evasion, and courts do not read it adversely.

Step 5 — Sequence disciplinary and criminal tracks separately. An NMC/State Medical Council disciplinary inquiry and a Section 106 BNS criminal case proceed on different evidentiary standards (professional misconduct vs. criminal negligence beyond reasonable doubt) and different timelines. Engage separate representation for each rather than assuming one defence serves both.

Step 6 — Invoke the medical-board-opinion safeguard before any arrest. Indian courts, following the Supreme Court's guidance in Jacob Mathew v. State of Punjab (2005) — principles that continue to apply to negligence prosecutions now framed under BNS Section 106 — have repeatedly held that a doctor should ordinarily not be arrested in a negligence case unless a prima facie opinion from an independent medical expert or board supports the allegation. If you or your institution are notified of a potential arrest without such an opinion having been sought, your legal counsel should raise this immediately as a procedural safeguard.

Step 7 — Communicate with the family throughout, not just at the point of crisis. A large proportion of BNS Section 106 complaints against doctors originate not from genuine negligence but from a breakdown in communication — families who felt unheard, uninformed, or dismissed in the run-up to an adverse outcome. Structured, empathetic, and documented communication (who was told what, and when) is simultaneously the best patient-experience practice and the most effective medico-legal risk-reduction strategy available to any clinician, at zero marginal cost.

A note on hierarchy and timing of drug/procedure documentation: where a procedure involves escalating interventions (e.g., stepwise uterotonic administration in postpartum haemorrhage, or sequential vasopressor titration in septic shock), record the time, dose, and clinical trigger for each escalation step rather than a single retrospective summary. In a Section 106 inquiry, a stepwise, time-stamped record is read as evidence of active, reasoned management; a single end-of-shift summary note is read — rightly or wrongly — as reconstructed after the fact.

Drug/procedure-choice pitfalls worth naming explicitly:

Prescribing outside your registered specialty scope (e.g., a physician performing a procedure customarily reserved for a surgical specialty) removes the ambiguity in your favour if a Section 106 case follows — scope-of-practice deviation is a common aggravating factor cited by prosecution experts.
Verbal orders without contemporaneous written/EMR confirmation are a recurring vulnerability in ICU and OT settings — the safest habit is a read-back-and-timestamp protocol for every verbal order.
Delegation to unregistered or under-supervised trainees for a "procedure" (per the Section 106(1) definition) may forfeit the doctor-specific protection for the supervising consultant if supervision was inadequate — supervision adequacy, not just delegation itself, is what gets scrutinised.

9. When to Escalate, When to Watch — Decision Thresholds

Situation	Watch and document	Escalate immediately (legal + institutional)
Unexpected death during/after a procedure, standard of care followed and documented	✅ Complete MLC/death summary; inform family with empathy; internal M&M review	Escalate only if family alleges negligence or requests police involvement
Family threatens or commits violence against staff	Note the threat contemporaneously	✅ Immediate — invoke hospital security protocol + state Medical Protection Act + consider Section 103(2)/117(4) BNS framing if injury results
Death "otherwise than under normal circumstances" within 7 years of marriage, dowry-harassment history alleged	—	✅ Immediate — Section 80 dowry-death provisions trigger mandatory police/magisterial inquest; do not issue a routine death certificate
Disputed consent in a reproductive/ART/termination case with allegation of concealed identity or false promise	✅ Review consent documentation	✅ If a formal complaint under Section 69 is filed, involve legal counsel before responding to any police notice
Registration/CME renewal lapse discovered after an adverse event	—	✅ Immediate — this affects the availability of the Section 106(1) protective proviso; regularise and inform your indemnity insurer
Routine MLC for simple hurt (Section 114) after minor assault	✅ Standard documentation, no independent legal escalation needed	Escalate only if injury reclassifies to grievous (15-day pain rule, fracture, etc.)

10. Memorable Summary — The "REGISTER" Mnemonic

To help trainees retain the practice-relevant core of the BNS at the bedside:

R — Renumbered, not identical: IPC 304A → BNS 106; IPC 375/376 → BNS 63–70; IPC 304B → BNS 80 E — Exemption is partial: Section 106(1) caps negligence-during-procedure at 2 years, not zero liability G — Grievous hurt has 8 defined categories (Section 116) — know them for every MLC I — Identity matters: the reduced-punishment shield applies only to a registered medical practitioner — keep your registration current S — Sexual offence provisions are broader (Section 69: deceit/false promise/identity concealment) — relevant to reproductive medicine consent disputes T — Timestamped, contemporaneous documentation is your strongest legal defence under the new evidence rules (BSA) E — Escalate mob violence using both state Protection Acts and awareness of BNS Section 103(2)/117(4) R — Read the Gazette, not just a website — the BNS text is still being judicially corrected; verify before you rely on any online reproduction

References

Indian Medical Association. IMA statement on rising medico-legal cases against doctors in India. New Delhi: IMA; 2024.
Ministry of Home Affairs, Government of India. The Bharatiya Nyaya Sanhita, 2023 (Act No. 45 of 2023). New Delhi: Gazette of India; 2023 Dec 25.
Bharatiya Nyaya Sanhita, 2023, § 106(1) (India), read with the National Medical Commission Act, 2019 (India).
Bharatiya Nyaya Sanhita, 2023, §§ 114–116 (India) (hurt and grievous hurt).
Bharatiya Nyaya Sanhita, 2023, § 124 (India) (voluntarily causing grievous hurt by acid, etc.).
Bharatiya Nyaya Sanhita, 2023, § 103(2) (India) (mob lynching).
Bharatiya Nyaya Sanhita, 2023, § 69 (India) (sexual intercourse by deceitful means).
Bharatiya Nyaya Sanhita, 2023, §§ 63–70 (India) (sexual offences).
Bharatiya Nyaya Sanhita, 2023, § 152 (India) (acts endangering sovereignty, unity and integrity of India).
Bharatiya Sakshya Adhiniyam, 2023 (Act No. 47 of 2023) (India) (rules on admissibility of electronic and digital records).
Jacob KS. Medical negligence and the law in India: understanding the standard of care. Indian J Med Ethics. 2023.
Press Information Bureau, Government of India. Clarification on Section 106(1) of the Bharatiya Nyaya Sanhita and its applicability to registered medical practitioners. New Delhi: PIB; 2024 Jul.
Debroy G. IMA demands withdrawal of new criminal law provision on doctors; Centre says no change. ETV Bharat. 2024 Jul 9.
Jharkhand High Court. Suo motu correction of drafting error in Section 103(2), Bharatiya Nyaya Sanhita, 2023 ("any other ground" vs "any other similar ground"). Ranchi: Jharkhand HC; 2025.
National Medical Commission. Registered Medical Practitioner (Professional Conduct) Regulations, 2023. New Delhi: NMC; 2023.

This review is intended for medical education purposes and does not constitute legal advice. Clinicians facing an actual medico-legal notice should consult qualified legal counsel and their institutional/indemnity insurer without delay.

Contemporary Myocarditis: Diagnostic Challenges and Management Strategies

A Grand Rounds Review for the Practicing Internist and Trainee

Dr Neeraj Manikath

1. The Case That Should Keep You Up at Night

A 24-year-old software engineer walks into casualty with two days of "flu" — myalgia, low-grade fever, and now a vague retrosternal heaviness he describes as "tightness, not really pain." His ECG shows diffuse, saddle-shaped ST elevation with PR depression. The resident signs him out as "viral pericarditis, reassure and discharge on ibuprofen." Six hours later he is found collapsed in the hospital toilet, in pulseless electrical activity. He is resuscitated, but transthoracic echocardiography now shows an ejection fraction of 20% with a globally hypokinetic, non-dilated left ventricle. Troponin, which was never sent on the first visit, comes back at 42 times the upper limit of normal.

This is not a rare, exotic diagnosis. It is myocarditis presenting exactly the way it usually presents — quietly, mimicking something more benign, in a young and otherwise healthy patient — right up until it doesn't.

Why this matters now, more than ever:

🩺 Epidemiological hook: Myocarditis is now recognized as a leading cause of sudden cardiac death in people under 35, accounting for up to 12% of such deaths in some autopsy series, and it is estimated to cause 1.5 million new cases worldwide annually. Yet clinically apparent myocarditis is believed to represent only a small fraction of the true burden — most cases are subclinical, and many fulminant presentations are diagnosed only at autopsy.

Three forces have converged over the last five years to make this an unusually active — and unusually confusing — area of internal medicine:

Immune checkpoint inhibitors (ICIs) have moved from niche oncology drugs to first-line therapy across a dozen cancers, bringing with them a rare but ferociously lethal form of fulminant lymphocytic myocarditis with reported mortality historically as high as 25–50%.
mRNA COVID-19 vaccination produced a well-characterized, usually self-limited, myopericarditis syndrome in young males — a "natural experiment" that sharpened our understanding of how mild, biopsy-negative-but-CMR-positive myocarditis behaves.
The 2024 ACC Expert Consensus Decision Pathway and the landmark 2025 ESC Guidelines for the Management of Myocarditis and Pericarditis — the first-ever joint ESC guideline unifying these two conditions — have fundamentally rewritten how we diagnose, risk-stratify, and treat this disease. If your mental model of myocarditis dates from your residency textbook, it is out of date.

This review distills what has changed, what has not, and — most importantly — what you actually need to do differently at the bedside on Monday morning.

2. Pathophysiology — Only What Changes Your Management

You do not need a paragraph on cytokine cascades to manage this patient well. You need to understand three phases, because each phase has a different treatment implication.

Phase 1 — Viral/triggered injury (Days 0–3). A cardiotropic insult — most often parvovirus B19, HHV-6, enterovirus/coxsackievirus, or now, non-infectious triggers like ICI-driven autoreactive T-cells or vaccine-associated innate immune activation — causes direct myocyte injury. Clinical implication: antiviral therapy has essentially no proven role here for common viral myocarditis; by the time patients present, active viral replication has usually already been cleared by the innate immune system.

Phase 2 — Autoimmune amplification (Days 4–14). This is the phase that actually destroys myocardium. T-cell-mediated and, in some phenotypes, antibody-mediated autoimmunity against cardiac self-antigens (often molecular mimicry with viral epitopes) drives ongoing myocyte necrosis and interstitial edema/fibrosis. Clinical implication: this is the window in which immunosuppression — when indicated — has biological plausibility, and it is why timing of endomyocardial biopsy (EMB) matters so much (see Section 7).

Phase 3 — Remodeling/chronic inflammatory cardiomyopathy. In a subset of patients, ongoing low-grade inflammation drives fibrofatty replacement, chamber dilation, and an arrhythmogenic substrate — the entity the new 2025 ESC guideline formally renames inflammatory cardiomyopathy, defined as chronic myocarditis with cardiac dysfunction and remodeling. Clinical implication: this is the phenotype that needs guideline-directed medical therapy (GDMT) for heart failure, an implantable defibrillator risk conversation, and — in genetically susceptible patients — cascade family screening, because a meaningful fraction of "chronic myocarditis" turns out to be a genetic arrhythmogenic cardiomyopathy unmasked by an inflammatory trigger.

🪙 Pearl: The single biggest conceptual shift in the 2025 ESC guideline is the move away from myocarditis as a single snapshot diagnosis and toward a disease continuum — acute myocarditis → resolution or chronic/relapsing inflammatory myopericardial syndrome → inflammatory cardiomyopathy. Ask yourself at every follow-up visit not "does this patient still have myocarditis?" but "which stage of the continuum is this patient in today?"

3. Clinical Pearls 🪙 — Bedside Truths That Aren't in the Textbook

🪙 Pearl 1 — The chest pain is often not the chief complaint that gets recognized. Patients frequently present with what sounds like a musculoskeletal or gastro-esophageal complaint — "tightness when I take a deep breath," "a burning after eating." A recent flu-like illness within the preceding 1–4 weeks, in a patient under 50 with atypical chest discomfort, should trigger a troponin and ECG before you reach for antacids or NSAIDs.

🪙 Pearl 2 — Troponin can be normal, especially in chronic/relapsing disease. In the acute fulminant phase troponin is almost always elevated, but in subacute or chronic inflammatory cardiomyopathy, troponin is frequently normal or only intermittently elevated because active myonecrosis has slowed even as inflammation and remodeling continue. A normal troponin does not exclude chronic inflammatory cardiomyopathy in a patient with new unexplained heart failure or ventricular arrhythmia.

🪙 Pearl 3 — Beware the "normal" ECG. A completely normal ECG is reassuring but does not rule out myocarditis; sensitivity of ECG abnormalities is only around 50%. Conversely, the combination of sinus tachycardia that is disproportionate to fever plus even minor, nonspecific ST-T changes in a young patient with a viral prodrome should raise your index of suspicion rather than lower it.

🪙 Pearl 4 — Fulminant myocarditis paradoxically has the best long-term prognosis if the patient survives the acute phase. This is one of the most counterintuitive and clinically important facts in the field. Patients who present in cardiogenic shock or with malignant arrhythmia (fulminant phenotype) but survive to discharge tend to have near-complete recovery of ejection fraction at long-term follow-up, in contrast to patients with a more indolent, "acute non-fulminant" presentation, who paradoxically have higher rates of progression to dilated cardiomyopathy. The lesson: aggressive hemodynamic support (including early mechanical circulatory support) in the sickest patients is not futile — it is precisely these patients who, if they survive, recover best.

🪙 Pearl 5 — Sinus tachycardia out of proportion to everything else is a red flag, not a nuisance vital sign. In an inpatient with viral symptoms and a heart rate that will not settle despite antipyretics and adequate volume status, think myocarditis before you think "anxiety" or "deconditioning."

4. Oysters 🦪 — The Hidden Gems Most Clinicians Miss

🦪 Oyster 1 — Eosinophilic myocarditis and DRESS. Any patient started on a new drug (especially anticonvulsants, allopurinol, or antibiotics) in the preceding 2–6 weeks who develops myocarditis with peripheral eosinophilia should be worked up for a hypersensitivity/DRESS-related eosinophilic myocarditis. This variant responds dramatically to corticosteroids and the causative drug must be permanently withdrawn — missing this diagnosis and treating it as "just viral myocarditis" denies the patient a highly treatable, steroid-responsive condition.

🦪 Oyster 2 — Giant cell myocarditis hides behind heart block. New-onset, unexplained high-grade AV block or ventricular tachycardia in a middle-aged adult, especially with a background of another autoimmune disease (thymoma, myasthenia gravis, inflammatory bowel disease), should prompt urgent consideration of giant cell myocarditis (GCM) — a rapidly progressive, often fatal disease if untreated, but one in which combination immunosuppression (corticosteroids plus a calcineurin inhibitor, with or without a T-cell antibody) dramatically improves transplant-free survival. GCM is a biopsy-or-die diagnosis: this is one of the few situations in myocarditis where EMB genuinely changes management within days.

🦪 Oyster 3 — Cardiac sarcoidosis masquerading as "idiopathic" chronic myocarditis/cardiomyopathy. Any patient labeled with unexplained non-ischemic cardiomyopathy plus conduction disease (especially heart block in a patient under 60) deserves a chest CT/hilar lymph node review and, where feasible, cardiac PET or CMR looking for patchy, patchy-basal-septal late gadolinium enhancement and FDG uptake. Sarcoidosis is a treatable mimic that is easy to lump into "burnt-out myocarditis" if you don't specifically look for it.

🦪 Oyster 4 — The post-viral "recovery" visit is where relapse is missed. A substantial minority of patients who look clinically well at 1–3 months have persistent late gadolinium enhancement or edema on repeat CMR — a marker associated with higher long-term arrhythmic risk even when the ejection fraction has normalized. Discharging a patient from follow-up purely on the basis of a normalized echo, without a follow-up CMR at 3–6 months in moderate-to-severe presentations, is a common and consequential oversight.

🦪 Oyster 5 — Athletes are a special population, and the return-to-play decision is a medicolegal minefield. Even mild, subclinical myocarditis diagnosed incidentally (e.g., during post-COVID cardiac screening) mandates a minimum 3–6 month exercise restriction with reassessment of biomarkers, rhythm (ambulatory monitoring), and ventricular function/CMR before clearance — because exercise during active myocardial inflammation is a recognized precipitant of malignant arrhythmia and sudden death in this population.

5. Clinical Hacks & Tips ⚡ — Shortcuts the Masters Actually Use

⚡ Hack 1 — Use the "chest pain + fresh troponin rise + normal (or near-normal) coronaries" triad as your mental trigger for CMR, not just cath lab clearance. Too often, once the angiogram is clean, the patient is labeled "MINOCA, discharge with reassurance" and the myocarditis workup stops there. Flip the sequence in your head: a clean angiogram in a patient with an troponin-positive ACS-mimicking presentation should activate, not terminate, your myocarditis workup.

⚡ Hack 2 — Order CRP and ESR even though they won't make the diagnosis. They are nonspecific, but a strikingly elevated CRP in a young patient with chest pain and a clean coronary angiogram is a useful "second data point" that nudges you toward requesting CMR sooner rather than watching and waiting.

⚡ Hack 3 — Learn to read (or at least request specifically) the updated Lake Louise Criteria on CMR reports. The updated criteria require evidence of both myocardial edema (T2-based criterion: regional/global T2 signal increase or elevated T2 mapping values) and non-ischemic myocardial injury (T1-based criterion: elevated native T1/ECV, or late gadolinium enhancement in a non-coronary distribution). Ancillary criteria (pericardial effusion, systolic dysfunction) support but do not replace these two pillars. If your radiology report doesn't explicitly address both T1- and T2-based criteria, ask for it — a report that just says "consistent with myocarditis" without stating which criteria were met is not good enough for a diagnosis that will shape months of management.

⚡ Hack 4 — Risk-stratify before you decide whether biopsy is needed, not after. Use a simple mental checklist: (a) hemodynamic instability or cardiogenic shock, (b) sustained ventricular arrhythmia or high-grade AV block, (c) rapidly deteriorating LV function despite supportive therapy, or (d) suspected giant cell myocarditis/cardiac sarcoidosis/eosinophilic myocarditis based on clinical clues above. Any one of these tips the balance firmly toward early EMB, because each represents a scenario where a specific, biopsy-confirmed diagnosis changes therapy immediately.

⚡ Hack 5 — For suspected ICI-myocarditis, treat the clock as your enemy. Do not wait for a "confirmatory" biopsy before starting high-dose corticosteroids if the clinical suspicion is even moderate (rising troponin plus new ECG change or arrhythmia in a patient on an ICI). Mortality in this entity is driven by delay; start pulse methylprednisolone empirically, hold the ICI, and biopsy/EMB findings can follow rather than lead the first dose of steroid.

⚡ Hack 6 — Screen for concomitant myositis/myasthenic crisis in every ICI-myocarditis patient. ICI myocarditis frequently co-occurs with immune-related myositis and myasthenia-like neuromuscular junction disease, and the combination markedly raises the risk of respiratory failure. Check a CK, and have a low threshold for pulmonary function testing / negative inspiratory force in these patients — this is the single biggest reason the field has moved toward early ICU-level monitoring for suspected ICI-myocarditis.

6. State-of-the-Art Updates — What Has Actually Changed Practice

1. The unified 2025 ESC Guidelines on Myocarditis and Pericarditis. For the first time, ESC has issued a single integrated guideline covering both conditions under the umbrella term "inflammatory myopericardial syndrome," reflecting how often they overlap clinically. The guideline introduces staged disease definitions, formalizes inflammatory cardiomyopathy as a distinct downstream entity, and provides structured diagnostic algorithms specific to three clinical presentations: acute chest pain, acute heart failure, and new arrhythmia.

2. The 2024 ACC Expert Consensus Decision Pathway (ECDP). This US-based document complements the ESC guideline with a practical, algorithmic approach for American practice, emphasizing a high index of suspicion in patients with chest pain, arrhythmia, or heart failure following a viral illness, autoimmune disease flare, or cardiotoxin exposure, and providing structured criteria for when EMB adds diagnostic/prognostic value that outweighs procedural risk.

3. Updated Lake Louise Criteria and mapping techniques. Native T1 and T2 mapping (quantitative, less operator-dependent than older qualitative sequences) has become the diagnostic backbone of non-invasive myocarditis diagnosis, with sensitivity now approaching that of biopsy in appropriately selected patients — reducing (though not eliminating) the need for invasive tissue sampling in stable patients.

4. The Seaport histopathological grading criteria for EMB. A quantitative, reproducible grading framework for endomyocardial biopsy has renewed clinical interest in biopsy, moving it beyond the older, poorly reproducible Dallas criteria and improving prognostic stratification when biopsy is performed.

5. Combination immunomodulation for ICI-myocarditis. Building on early single-agent abatacept data, current evidence supports early combination therapy with abatacept plus the JAK inhibitor ruxolitinib on top of corticosteroids for severe/steroid-refractory ICI-myocarditis, with observational data suggesting a dramatic reduction in mortality compared with corticosteroids plus later, sequential second-line agents. Randomized confirmation (the ATRIUM trial) is ongoing, but the observational signal has already shifted practice at experienced centers toward earlier, combined immunosuppression rather than a slow "step-up" ladder.

6. Mechanistic and precision therapies on the horizon. Interleukin-1 inhibition (anakinra), colchicine, and other mechanism-targeted immunomodulators are under active investigation for acute and relapsing myocarditis/pericarditis, building on the established efficacy of these agents in idiopathic recurrent pericarditis.

7. mRNA vaccine-associated myocarditis — reassuring long-term data. Large cohort follow-up of predominantly young male patients with mRNA COVID-19 vaccine-associated myopericarditis has shown that the overwhelming majority have a mild clinical course with rapid symptomatic and biomarker recovery, though a meaningful minority retain subtle CMR abnormalities at follow-up, reinforcing the importance of structured follow-up imaging rather than presuming complete resolution from clinical recovery alone.

7. Diagnostic Nuances — Separating Good from Great

History — the questions residents forget to ask:

Exact timeline of viral prodrome relative to cardiac symptoms (autoimmune-phase myocarditis classically lags the viral illness by 1–3 weeks).
Complete drug history over the preceding 8 weeks, explicitly including over-the-counter, herbal, and recreational substances (cocaine and amphetamines cause a distinct catecholaminergic/hypersensitivity myocarditis).
Full oncology history and exact ICI regimen/cycle number — myocarditis risk is highest in the first 3 months of therapy and with combination CTLA-4/PD-1 blockade.
Family history of sudden cardiac death or cardiomyopathy — because an inflammatory trigger can unmask an underlying genetic arrhythmogenic cardiomyopathy, and this changes the long-term surveillance plan for the whole family.

Examination pearls:

A new S3 gallop or a friction rub in a young patient with chest pain and fever is far more specific for myopericarditis than either finding alone.
Look specifically for signs that point away from myocarditis and toward a mimic: asymmetric limb pulses/blood pressures (aortic dissection), a pleuritic component worsened by lying flat and eased by sitting forward (isolated pericarditis), or focal wall-motion territory findings on bedside echo (still favors ischemia until proven otherwise).

Investigations — the sequencing that matters:

ECG and high-sensitivity troponin in every patient with the clinical triad (chest pain/dyspnea/palpitations + recent viral illness + no clear alternative explanation).
Transthoracic echocardiography early — not primarily to diagnose myocarditis (it cannot), but to exclude a regional wall motion abnormality pointing to true ischemia, quantify LV function, and screen for a pericardial effusion/tamponade physiology that needs urgent action.
Coronary evaluation (invasive angiography or CT coronary angiography depending on pretest probability and age) whenever the presentation could plausibly be ischemic — myocarditis is, in significant part, a diagnosis of exclusion in the acute chest-pain pathway.
CMR is the pivotal non-invasive test once ischemia is reasonably excluded, ideally performed within the first 2–3 weeks of symptom onset, when sensitivity for edema is highest.
EMB reserved for the specific high-value scenarios in Hack 4 above — not a routine test for every troponin-positive, CMR-positive patient with a benign trajectory.

🪙 Diagnostic pearl: CMR performed too early (within 48–72 hours) or too late (beyond 3–4 weeks) can be falsely reassuring, because acute edema signal takes some hours to develop and resolves over subsequent weeks. If your index CMR is negative but clinical suspicion remains high, repeat it — do not abandon the diagnosis on the strength of a single, poorly timed scan.

8. Management Intricacies — Drugs, Doses, Timing, and Pitfalls

General supportive care (applies to essentially all patients):

Bed rest / restriction from vigorous exercise for a minimum of 3–6 months, reassessed with biomarkers, rhythm monitoring, and imaging before clearance — this single, unglamorous intervention is arguably the highest-yield "treatment" in mild-to-moderate disease.
Standard GDMT (ACE-inhibitor/ARB or ARNI, beta-blocker once hemodynamically tolerated, mineralocorticoid receptor antagonist, SGLT2 inhibitor) for any patient with reduced ejection fraction, exactly as you would for any other cause of heart failure with reduced EF — myocarditis does not exempt a patient from evidence-based heart failure therapy.
Avoid NSAIDs in patients with significant LV systolic dysfunction (they can worsen fluid retention and afterload); they remain reasonable for isolated pericarditis-predominant presentations with preserved LV function.
Colchicine has an established role in reducing pericarditis recurrence in the myopericarditis-predominant phenotype and is increasingly used as adjunctive therapy.

Immunosuppression — who, when, how:

Idiopathic lymphocytic myocarditis without a specific treatable cause: immunosuppression is not routinely recommended based on current evidence; supportive/GDMT-based management remains the default.
Giant cell myocarditis: combination immunosuppression (high-dose corticosteroids plus a calcineurin inhibitor such as cyclosporine, often with anti-thymocyte globulin or another T-cell-directed agent) started promptly once biopsy-confirmed, continued for an extended taper, with early referral to an advanced heart failure/transplant center given the risk of rapid deterioration.
Eosinophilic/hypersensitivity myocarditis: withdraw the offending drug immediately; high-dose corticosteroids produce a typically rapid and dramatic response.
Cardiac sarcoidosis: corticosteroids as first-line immunosuppression, with steroid-sparing agents (methotrexate, mycophenolate, or biologic therapy) for relapsing or steroid-refractory disease, alongside arrhythmia-specific management (device therapy is frequently required given the conduction disease burden).
ICI-associated myocarditis: hold the ICI; start pulse-dose intravenous methylprednisolone (typically 500–1000 mg/day for 3–5 days) without waiting for biopsy confirmation if clinical suspicion is moderate-to-high; escalate early to combination second-line immunosuppression (abatacept plus ruxolitinib is the emerging evidence-based combination) for severe, steroid-refractory, or rapidly progressive disease rather than a slow sequential step-up — the data now favor early combination over "wait and see if steroids alone work."

Arrhythmia management pitfalls:

Avoid reflexive permanent pacemaker/ICD implantation in the acute phase for AV block or ventricular arrhythmia — a meaningful proportion of conduction disease in acute myocarditis is reversible as inflammation resolves, and a wearable cardioverter-defibrillator is a useful bridging strategy while allowing time for recovery before committing to a permanent device.
In giant cell myocarditis and cardiac sarcoidosis, by contrast, the arrhythmic substrate is often fixed/fibrotic, and device therapy decisions should not be deferred on the assumption of spontaneous recovery.

Mechanical circulatory support:

In fulminant myocarditis with cardiogenic shock, do not delay escalation to temporary mechanical circulatory support (intra-aortic balloon pump, percutaneous ventricular assist device, or veno-arterial ECMO) while "waiting to see" — early institution, before end-organ hypoperfusion sets in, is associated with better recovery, and (per Pearl 4) these are precisely the patients most likely to recover fully if they survive the acute insult.

🪙 Management pearl: Resist the urge to start a beta-blocker at full dose on day one in a patient with acute myocarditis and borderline hemodynamics — negative inotropy during active myocardial inflammation can precipitate decompensation. Start low, go slow, and uptitrate as the acute inflammatory phase settles, exactly as you would in any fresh, hemodynamically fragile new heart failure presentation.

9. When to Escalate, When to Watch — Decision Thresholds

Admit and monitor closely (telemetry-capable bed, minimum):

Any elevated troponin with ECG change, arrhythmia, or even mild LV dysfunction.
Any patient on active ICI therapy with a rising troponin, irrespective of symptom severity — this population deteriorates fast and unpredictably.

Escalate to ICU / advanced cardiac care:

Hemodynamic instability, sustained ventricular arrhythmia, or high-grade AV block.
Rapidly worsening LV function on serial echocardiography despite supportive measures.
Any ICI-myocarditis patient with concomitant myositis/neuromuscular involvement — because respiratory failure can be abrupt.

Refer for endomyocardial biopsy (cardiology/advanced heart failure input):

Any of the "red flag" criteria in Hack 4 (Section 5) — instability, malignant arrhythmia/high-grade block, rapid deterioration despite treatment, or suspected giant cell myocarditis/eosinophilic myocarditis/sarcoidosis.

Refer to advanced heart failure/transplant center:

Suspected or confirmed giant cell myocarditis (mortality without treatment is extremely high; even with treatment, this is a disease best managed where mechanical circulatory support and transplantation are immediately available).
Cardiogenic shock not responding to first-line supportive measures — early referral, before the patient is peri-arrest, dramatically changes options and outcomes.

Safe to watch as an outpatient (with structured follow-up):

Mild, hemodynamically stable, biomarker-limited disease with preserved LV function, no arrhythmia, and no red-flag features — provided a clear follow-up plan (clinical review, biomarkers, and repeat imaging at 3–6 months, exercise restriction counseling) is documented before discharge.

🪙 Escalation pearl: The decision to escalate should be driven far more by trajectory than by any single value. A troponin that is falling on serial measurement in a hemodynamically stable patient is reassuring even if the peak was very high; a troponin that is rising, even modestly, in a patient who "looks fine" is not.

10. Summary Table and Memory Aid

Mnemonic — Remember myocarditis with "M-Y-O-C-A-R-D-I-T-I-S":

Letter	Reminds you to...
M	Mimics of ACS — always exclude coronary disease first in the chest-pain presentation
Y	Young patients + viral prodrome = raise your index of suspicion
O	Oyster diagnoses — eosinophilic, giant cell, sarcoid — actively look for treatable subtypes
C	CMR is the pivotal non-invasive test; time it right (2–3 weeks post-onset)
A	Avoid NSAIDs if LV dysfunction present; avoid early full-dose beta-blockade
R	Red flags (shock, malignant arrhythmia, high-grade block, rapid deterioration) mandate biopsy/ICU
D	Drugs and toxins — always take a meticulous 8-week exposure history
I	ICI myocarditis — hold the drug, start steroids early, escalate to combination immunosuppression fast
T	Trajectory, not a single value, drives escalation decisions
I	Inflammatory cardiomyopathy — the chronic downstream phenotype needing GDMT + genetic/family screening
S	Sport/exercise restriction for 3–6 months with re-imaging before clearance

Quick-reference summary table

Domain	Key Point
Best initial non-invasive test	Cardiac MRI (updated Lake Louise criteria: T1- and T2-based evidence)
When biopsy is essential	Shock, malignant arrhythmia/high-grade AV block, rapid deterioration, suspected giant cell/eosinophilic/sarcoid myocarditis
Best long-term prognosis	Paradoxically, fulminant presentations who survive the acute phase
First-line therapy, idiopathic lymphocytic myocarditis	Supportive care + standard heart failure GDMT; routine immunosuppression not recommended
First-line therapy, ICI-myocarditis	Hold ICI + early pulse corticosteroids; escalate early to abatacept + ruxolitinib if severe/refractory
Steroid-responsive "don't miss" mimic	Eosinophilic/hypersensitivity (drug-induced) myocarditis
Exercise restriction	Minimum 3–6 months, reassess before clearance
New unifying concept (2025 ESC)	Inflammatory myopericardial syndrome → inflammatory cardiomyopathy as chronic phenotype

11. References (Vancouver Style)

Schulz-Menger J, Collini V, Gröschel J, Adler Y, Brucato A, Caforio ALP, et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. Eur Heart J. 2025;46(41):3952-4041.
Kociol RD, Cooper LT, Fang JC, Moslehi JJ, Pang PS, Sabe MA, et al. 2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024;84(25):2628-2661.
Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72(24):3158-3176.
Salem JE, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Allenbach Y, et al. Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov. 2023;13(5):1100-1115.
Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019;380(24):2377-2379.
Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020;9(2):e013757.
Puzzo L, Amico F, Sciacca A, Vecchio GM, Caltabiano R, Ardiri A, et al. Advances in management of complicated myocarditis and inflammatory cardiomyopathy. Curr Treat Options Cardiovasc Med. 2026;28(1):15.
Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail. 2020;13(11):e007405.
Ammirati E, Veronese G, Brambatti M, Merlo M, Cipriani M, Potena L, et al. Fulminant versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2019;74(3):299-311.
Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O'Connor CM, Felker GM. Troponin elevation in heart failure: prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010;56(14):1071-1078.
Kytö V, Sipilä J, Rautava P. The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood. Heart. 2013;99(22):1681-1684.
Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation. 2016;134(23):e579-e646.
Cooper LT Jr, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the AHA, ACC, and ESC. Circulation. 2007;116(19):2216-2233.
Ammirati E, Moslehi JJ. Diagnosis and treatment of acute myocarditis: a review. JAMA. 2023;329(13):1098-1113.
Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med. 2021;385(23):2132-2139.

This review reflects evidence and guideline updates available as of mid-2026, including the 2025 ESC integrated myocarditis/pericarditis guideline and the 2024 ACC expert consensus decision pathway. As with all rapidly evolving fields, clinicians should verify drug doses and evolving trial data (e.g., the ongoing ATRIUM abatacept trial) against current local protocols before applying them to individual patients.